Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GP681 in pediatric uncomplicated influenza
NCT06643156Phase 1Completed
- Sponsor
- Jiangxi Qingfeng Pharmaceutical Co. Ltd.
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of suraxavir marboxil in influenza, sponsored by Jiangxi Qingfeng Pharmaceutical Co. Ltd. Primary endpoint: Number of Participants with Adverse Events (AEs). Started Sep 2024; status: completed.
02
Drugs
suraxavir marboxil
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06643156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643156.